Investigational Drug Information for Losmapimod
✉ Email this page to a colleague
What is the development status for investigational drug Losmapimod?
Losmapimod is an investigational drug.
There have been 15 clinical trials for Losmapimod.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophies, and Acute Coronary Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and Royal Brompton & Harefield NHS Foundation Trust.
There are sixty-four US patents protecting this investigational drug and nine hundred and eighty-four international patents.
Summary for Losmapimod
| US Patents | 64 |
| International Patents | 984 |
| US Patent Applications | 237 |
| WIPO Patent Applications | 147 |
| Japanese Patent Applications | 25 |
| Clinical Trial Progress | Phase 3 (2022-06-01) |
| Vendors | 53 |
Recent Clinical Trials for Losmapimod
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics | Phase 3 |
| Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets | Fulcrum Therapeutics | Phase 1 |
| Losmapimod Safety and Efficacy in COVID-19 | Fulcrum Therapeutics | Phase 3 |
Clinical Trial Summary for Losmapimod
Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod
US Patents for Losmapimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Losmapimod | ⤷ Sign Up | Compounds .alpha..sub.v.beta..sub.6 integrin antagonists | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | ⤷ Sign Up |
| Losmapimod | ⤷ Sign Up | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | ⤷ Sign Up |
| Losmapimod | ⤷ Sign Up | 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors | Chiesi Farmaceutici S.p.A. (Parma, IT) | ⤷ Sign Up |
| Losmapimod | ⤷ Sign Up | Aminoester derivatives | CHIESI FARMACEUTICI S.p.A. (Parma, IT) | ⤷ Sign Up |
| Losmapimod | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Losmapimod
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Losmapimod | Argentina | AR101995 | 2034-09-26 | ⤷ Sign Up |
| Losmapimod | Australia | AU2015320859 | 2034-09-26 | ⤷ Sign Up |
| Losmapimod | Brazil | BR112017006253 | 2034-09-26 | ⤷ Sign Up |
| Losmapimod | Canada | CA2962326 | 2034-09-26 | ⤷ Sign Up |
| Losmapimod | China | CN107074849 | 2034-09-26 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
